Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Kobayashi: Operating Profits Down 4.4%, Hurt by Cool Summer
December 8, 2003
- BIO-Asia Clinical Stage Partnering Conference to Give Makers Good Chance: Mr Tanaka, Consultant
December 8, 2003
- OTC NEWS IN BRIEF
December 8, 2003
- Kaken to Remain Independent, Focus on Niche Markets: President Inui
December 8, 2003
- MEDICAL DEVICE NEWS IN BRIEF
December 8, 2003
- EU's Clinical Trial Directive Discussed: Quintiles Seminar
December 8, 2003
- DIAGNOSTIC NEWS IN BRIEF
December 8, 2003
- Resistance to Use of Contract MRs Weakening: Fuji-keizai Survey
December 8, 2003
- WORLD NEWS IN BRIEF
December 8, 2003
- BUSINESS NEWS IN BRIEF
December 8, 2003
- We Wish to Become a Global Mega-Player after 2005: Dr Aoki of Fujisawa
December 8, 2003
- Approval of 3 Drugs Including Atazanivir Recommended
December 8, 2003
- Semi-annual Business Result
December 8, 2003
- Nippon Shinyaku: Sales Up Slightly, Profits Hit by Higher Costs
December 1, 2003
- Rewards for Innovativeness in New Drugs to Be Needed: Mr Ager of EFPIA
December 1, 2003
- Kaken: Ordinary Profits Down, but R&D Tax Credit Boosts Net Profits
December 1, 2003
- ICH-6 in Osaka Focuses on New Horizons and Future Challenges (1)
December 1, 2003
- Meiji Seika: Drug Division Sales Up 6.5% to \49.5 Bil.
December 1, 2003
- Chuikyo Discusses NPA Recommendation, Consumer Prices
December 1, 2003
- Suzuken: Consolidated Sales Up 15% to \558.1 Bil.
December 1, 2003
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…